Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc., as indicated in the metadata) on June 7, 2022. The report addresses regulatory compliance with Nasdaq listing standards and announces the schedule for the 2022 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance required for regulatory compliance:
- Stock Price: The common stock maintained a closing bid price of $1.00 or greater for ten consecutive trading days from May 23, 2022, through June 6, 2022.
Material Changes
The primary material change reported is the regained compliance with the Nasdaq Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Previous Status: On February 16, 2021, the company received notice of non-compliance due to a closing bid price below $1.00 for 30 consecutive trading days.
- Current Status: On June 7, 2022, Nasdaq issued a Compliance Letter confirming the company met the requirement, and the matter is now considered closed.
Outlook, Management Commentary, and Corporate Events
2022 Annual Meeting of Stockholders:
- Date: August 15, 2022.
- Record Date: July 15, 2022.
Stockholder Proposals and Director Nominations:
- Deadline: June 18, 2022.
- Requirement: Proposals under Rule 14a-8 and notices for director nominations must be received by the Company Secretary by this date to be included in proxy materials or considered timely.
Investor Verification Checklist
- Verify the company name is Catalyst Biosciences, Inc. (Ticker: CBIO), not Gyre Therapeutics.
- Confirm the stock price has remained above $1.00 to maintain Nasdaq listing status.
- Note the June 18, 2022 deadline for submitting stockholder proposals or director nominations for the upcoming annual meeting.
- Review the forthcoming proxy statement for details on the August 15, 2022, Annual Meeting.